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Abstract: Given that oxidative stress plays a major role in pancreatic β-cell 
dysfunction and ultimate destruction, as well as in different complications of 
diabetes, therapy with antioxidants has assumed an important place in the 
management of diabetes. The relatively limited effects of established antioxi-
dant compounds have stimulated efforts to develop new therapeutic strategies, 
e.g. to increase the endogenous antioxidant defences through pharmacological 
modulation of key antioxidant enzymes. Plant extracts are gaining popularity in 
treating diabetes because many substances synthesized by higher plants and 
fungi possess antioxidant activities and can prevent or protect tissues against 
the damaging effects of free radicals. This review summarizes experimental 
models of diabetes and possible mechanisms that lie behind the antioxidative 
effects of α-lipoic acid (LA), a powerful antioxidant and compound that sti-
mulates cellular glucose uptake, as well as of plant extracts from sweet chest-
nut (Castanea sativa), edible mushroom (Lactarius deterrimus) and natural 
products containing β-glucans in the treatment of diabetes. Their roles in pre-
venting pancreatic β-cell death and in ameliorating the effects of severe dia-
betic complications are discussed. 
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Diabetes mellitus is a chronic metabolic disease with an aetiology linked to 
both genetic and environmental factors. Diabetes has become a global health 
problem due to its high incidence and latent harmful and lethal effects. Accord-
ing to the World Health Organization (WHO),1 347 million people worldwide 
have diabetes, which has greatly increased the cost of treating both the disease 
and its numerous devastating complications. According to the International Dia-
betes Federation (IDF), 4.6 million people die each year from the consequences 
of diabetes,2 with more than 80 % of diabetes-related deaths occurring in low and 
middle income countries.1 According to The Public Health Institute of Serbia 
“Dr Milan Jovanović Batut”,3 630,000 people or 8.2 % of the Serbian population 
suffer from diabetes and about 3,000 diabetics die each year. Type 1 diabetes 
(T1D) is characterized by destruction of pancreatic β-cells and thereby loss of 
insulin secretion. Type 2 diabetes (T2D) is associated with progressive insulin 
resistance and β-cell dysfunction. Deficiency of insulin secretion or action in 
diabetes causes prolonged hyperglycaemia that in turn leads to severe diabetic 
complications, such as retinopathy, neuropathy, nephropathy, cardiovascular 
problems, liver disease and limb amputation. Diabetes treatment includes insulin 
injection in combination with application of hypoglycaemic drugs. However, 
current control of diabetes-associated complications and mortality is not satis-
factory. 
Limitations in diabetes treatment have stimulated efforts to develop new the-
rapeutic strategies. Growing evidence in both experimental and clinical studies 
suggests that oxidative stress plays an important role in pancreatic β-cell des-
truction/dysfunction and subsequent complications of diabetes. Therefore, stra-
tegies for diabetes management include antioxidant protection. However, estab-
lished antioxidant compounds, such as vitamins C and E, have yielded limited 
effects, indicating the necessity for examination of other antioxidant compounds. 
Given that antioxidant enzyme expression and function is deregulated in dia-
betes, pharmacological modulation of key enzymes that are responsible for re-
ducing the oxygen radical load is a potentially more effective approach than the 
use of systemic antioxidants.4,5 It is therefore imperative to continuously identify 
new products with antioxidant activities for use in “causal” therapy of diabetes.6 
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Plant extracts are gaining popularity in diabetes treatment because of their effi-
cacy, low incidence of side effects, their accessibility and low cost. Identifying 
new agents from plants with hypoglycaemic and antioxidative activities is of 
great importance. In this review, a summary will be given of the ameliorating 
effects and potential mechanisms of the actions of the known antioxidant com-
pound α-lipoic acid (LA), extracts of the sweet chestnut (Castanea sativa), edible 
mushroom (Lactarius deterrimus) and their combination (MIX Cs/Ld), and of a 
β-glucan-enriched extract in the treatment of diabetes, i.e., in the prevention of 
pancreatic β-cell death and amelioration of the severe complications in diabetes. 
Experimental models of diabetes will also be discussed. 
2. OXIDATIVE STRESS IN THE DEVELOPMENT OF DIABETES 
AND ITS COMPLICATIONS 
Oxidative stress is generally defined as a persistent imbalance between the 
concentrations of generated highly reactive free radical reactive oxygen species 
(ROS) and reactive nitrogen species (RNS) on the one hand and the antioxidant 
defence of the organism on the other. Hyperglycaemia promotes the formation of 
elevated levels of free radicals, especially ROS, via different routes of activation: 
glucose autoxidation,7 non-enzymatic protein glycation,8 increased metabolism 
of glucose through the hexosamine pathway,9 excessive activation of the polyol 
pathway by unused glucose,10 and by advanced glycation end-products (AGE) 
formed by the interaction of glucose with proteins.11 One of the main sources of 
free radicals in diabetes is glucose autoxidation.12 In a transition-metal dependent 
reaction, the enediol form of glucose is oxidized to an enediol radical anion that 
is converted into reactive ketoaldehydes and to superoxide anion radicals (O2•–). 
The superoxide anion radicals undergo dismutation to hydrogen peroxide (H2O2), 
which, if not degraded by catalase (CAT) or glutathione peroxidase (GSH-Px), in 
the presence of transition metals can lead to the production of extremely reactive 
hydroxyl radicals (OH·).13 Superoxide anion radicals can also react with nitric 
oxide (NO) to form reactive peroxynitrite. Peroxynitrite is chemically unstable 
under physiological conditions and reacts with all major classes of biomolecules, 
mediating cytotoxicity,14 AGE signalling, through the receptor for AGE (RAGE), 
and inactivation of enzymes by altering their structure,15 thereby supporting ad-
ditional free radical accumulation.16 Excess levels of free radicals damage cel-
lular proteins, lipids and nucleic acids, leading to cell death in various tissues (the 
cardiovascular system, retina, kidneys, liver, peripheral nerves and skin), thus 
contributing to diabetes complications. The harmful effects of ROS and RNS are 
neutralized by the endogenously expressed antioxidant enzymes (superoxide dis-
mutases (SODs), CAT, GSH-Px) and non-enzymatic antioxidants (endogenous 
reduced glutathione (GSH) and exogenous vitamins C and E).7 
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3. EXPERIMENTAL MODELS OF DIABETES MELLITUS 
Experimental models play an important role in understanding diabetes, as 
well as in evaluating the pharmacological actions of different agents. Isolated rat, 
mouse and human pancreatic islets are used for investigating the mechanisms 
involved in β-cell dysfunction and destruction in diabetes.17–19 The use of pri-
mary β-cells in research is limited because their purification and maintenance of 
native characteristics is technically demanding. To overcome these limitations, 
investigators have produced immortalized β-cell lines.20 The most widely used 
insulin-secreting cell lines are rat insulinoma cells (RIN and INS-1), hamster 
pancreatic β-cells (HIT) and mouse insulinoma cells (MIN and βTC). Although 
the properties of the cell lines differ slightly from those of primary β-cells, they 
are extremely valuable tools for the study of molecular events underlying β-cell 
function, including the testing of the effects of potential drugs in diabetes mana-
gement. 
Several animal models have been developed for in vivo studies of diabetes 
and anti-diabetic agents. Genetic models of diabetes include the spontaneous 
development of diabetes in rats21,22 and genetically engineered diabetic mice to 
either overexpress (transgenic) or underexpress (knockout) proteins thought to 
play a key role in glucose metabolism.23,24 Surgical model of diabetes include 
the complete removal of the pancreas (pancreatectomy) or partial pancreatectomy 
(more than 80 % resection in rats). These models allow for the evaluation of the 
effect of natural products in an animal without the interference of side effects 
induced by chemical drugs used to induce experimental diabetes.25,26 However, 
these models are rarely used because of the highly specialized technical skills 
required and the high percentage of animal mortalities. 
Chemical induction is the most popular procedure for inducing diabetes in 
experimental animals and has been proven repeatedly to be useful for the study 
of multiple aspects of the disease. Streptozotocin (STZ), a naturally occurring 
glucosamine–nitrosourea compound is the most frequently used drug for experi-
mental diabetes induction in laboratory rats. As a glucose analogue, STZ selecti-
vely accumulates in β-cells via the glucose transporter (GLUT2). As an alkyla-
ting agent, STZ fragments DNA.27 DNA damage induces activation of the DNA 
repair process that leads to enhanced ATP dephosphorylation, which supplies a 
substrate for xanthine oxidase, resulting in ROS formation. The diabetogenic 
effect of STZ also relies on its ability to liberate NO which participates in DNA 
damage. STZ is capable of inducing T1D either by direct β-cell destruction after 
administration of a single large dose of STZ (65–150 mg kg–1),28 or via an im-
mune cell-mediated mechanism using multiple low doses of STZ (40 mg kg–1).29 
A single high dose of STZ causes extensive non-physiological β-cell necrosis, 
whereas multiple low doses of STZ induce limited apoptosis, which elicits an 
autoimmune reaction that eliminates the remaining cells.30 There is a general 
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consensus that the experimental model of multiple low-dose STZ-induced dia-
betes resembles more closely the in vivo state of insulinaemia, reflecting its 
autoimmune nature and resulting onset of diabetes. 
4. NUMEROUS ANTIOXIDANT COMPOUNDS AND PLANT EXTRACTS 
IN DIABETES MANAGEMENT 
A number of studies have demonstrated that treatment with antioxidants 
reduces oxidative stress and alleviates diabetic complications in diabetic subjects 
and animals.31 Vitamins C and E, and LA are the most studied antioxidants. 
Vitamin C is the strongest physiological antioxidant. It regenerates vitamin E 
through redox cycling and increases intracellular GSH levels.32 Small clinical 
trials showed that vitamin E, as well as a combination of vitamin E and C, 
exerted beneficial effects on the cardiovascular system in T1D patients33,34 and 
improved renal function in T2D patients.35 However, in large-scale clinical trials, 
i.e., Heart Outcomes Prevention Evaluation (HOPE),36 Secondary Prevention 
with Antioxidants of Cardiovascular Disease in End Stage Renal Disease 
(SPACE),37 the Primary Prevention Project (PPP)38 and the Study to Evaluate 
Carotid Ultrasound Changes in Patients Treated With Ramipril and Vitamin E 
(SECURE),39 vitamin E treatment failed to provide any benefit in cardiovascular 
disorders or nephropathy. A multifactorial approach is more efficient than con-
ventional therapy for the prevention of oxidative stress-induced vascular compli-
cations in diabetes.40 Daily supplementation of vitamin C (250 mg), vitamin E 
(100 mg), folic acid (400 mg) and chromium picolinate (100 mg) in combination 
with multifactorial intensive therapy resulted in an almost 50 % decrease in 
cardiovascular incidents. 
LA stimulates cellular glucose uptake and possesses direct radical-scaveng-
ing and metal-chelating properties, and has the ability to regenerate other anti-
oxidants.41 Naturally occurring LA is present in low amounts in vegetables and 
animal tissues where it functions as a coenzyme in pyruvate dehydrogenase and 
α-ketoglutarate dehydrogenase mitochondrial reactions. The most abundant plant 
sources of LA are spinach, followed by broccoli and tomatoes. Synthetic LA has 
a relatively long history of use as a nutritional supplement in European countries 
and the United States, and as a therapeutic agent in the treatment of diabetic 
neuropathy and retinopathy.42 Studies with LA, i.e., Alpha Lipoic Acid in Dia-
betic Neuropathy (ALADIN) I, II and III,43–45 and Deutsche Kardiale Autonome 
Neuropathie (DEKAN),46 investigated the effect of LA treatment on sensory 
symptoms of diabetic polyneuropathy as assessed by the Total Symptom Score 
(SYDNEY)47 and meta-analysis48 led to its approval for the treatment of diabetic 
neuropathy, and initial results are more promising than those obtained with vita-
min E. Parallel with LA use, questions of its safety and effectiveness have been 
raised. A daily oral dose of 600 mg provides an optimum risk-to-benefit ratio in 
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human diabetics.42 LA supplementation at higher doses causes a few serious side 
effects, such as gastrointestinal disorders and allergic reactions. Selection of the 
appropriate dose of LA for application in diabetes is critical.49 As cholestatic 
hepatitis was probably caused by LA (600 mg day–1) treatment of symptomatic 
diabetic neuropathy,50 the authors suggest liver enzyme levels be monitored 
during LA treatment. 
Phytochemicals, the bioactive non-nutrient plant compounds in fruit, vege-
tables, grains and other plant foods, have been linked to reductions in the risk of 
major chronic diseases. It is estimated that more than 5,000 phytochemicals have 
been identified, but that a large percentage remains unknown.51 Phytochemicals 
with antioxidative effects include a variety of phytosterols, terpenes and espe-
cially polyphenols, such as flavonoids, tannins and phenylpropanoids. A direct 
correlation between the total phenolic content and antioxidant capacity was esta-
blished and explained through a number of different mechanisms, such as free 
radical scavenging, metal ion chelation and hydrogen donation.52–54 
There is a growing interest for the use of plant extracts because purified 
bioavailable phenolic compounds are difficult to obtain, and because extracts 
sometimes have better antioxidant activities than the pure molecules.55 Taken 
alone, the individual antioxidants studied in clinical trials do not appear to have 
consistent diabetes-preventive effects. Studies of different fruit combinations 
showed greater total antioxidant activity because of their additive and synergistic 
relationships.51 An isolated pure compound can lose its bioactivity or may not 
exhibit it in the same way as when present in whole foods. This partially explains 
why no single antioxidant can replace a combination of natural phytochemicals 
contained in plants in accomplishing health benefits. Although plants are rich in 
antioxidants, individual “antioxidant” molecules cannot just be extracted, packed 
in pills in high doses and expected to provide high levels of protection.5 Pills or 
tablets cannot mimic the balanced natural combination of phytochemicals present 
in plants. Phytochemicals differ in molecular size, polarity, and solubility, and 
these differences may affect the bioavailability and distribution of each phytoche-
mical in different macromolecules, sub-cellular organelles, cells, organs, and tis-
sues. These observations have lead to the concept that antioxidants are better im-
plemented through whole food consumption than as expensive dietary supple-
ments. Further research on the health benefits of phytochemicals in whole foods 
is of essential interest.56  
Many investigations have studied the effects of antioxidant components of 
plants on diabetes and its complications. Antioxidant and antihyperglycemic pro-
perties of Allium cepa L., Anoectochilus formosanus, Lycium barbarum, Cassia 
fistula L., Aloe vera, Vitis aestivalis and Coffea arabica in chemical models of 
diabetes have been demonstrated.57–63 In addition, Centaurium erythrea and 
Aegle marmelos extracts and quercetin, a flavonoid antioxidant present in many 
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plants, alleviate STZ-induced cell damage and oxidative stress in rat pancreas.65–66 
Medicinal plants with proven antidiabetic and related beneficial effects in dia-
betes treatment also include: Allium sativum, Eugenia jambolana, Momordica 
charantia, Ocimum sanctum, Phyllanthus amarus, Pterocarpus marsupium, 
Tinospora cordifolia, Trigonella foenum graecum and Withania somnifera.67 
5. NOVEL MECHANISM OF ANTIOXIDATIVE EFFECT OF LA IN DIABETES 
Numerous studies indicate that LA exerts its antioxidant effect by increasing 
the endogenous defence response of cells through enhanced synthesis of endo-
genous low molecular weight antioxidants and antioxidant enzymes.42 The levels 
of antioxidant enzymes are regulated by gene expression, as well as by post-
translational modifications.68 Emerging data indicates that the post-translational 
addition of β-N-acetylglucosamine (O-GlcNAc) to proteins has a role in the 
aetiology of diabetes.69 O-linked glycosylation of certain proteins is increased in 
hyperglycaemia because of activation of the hexosamine pathway, which pro-
duces uridine-diphospho-N-acetylglucosamine (UDP-GlcNAc), a substrate for 
the glycosylation reaction. This modification is dynamic and may disturb the 
normal dynamic balance between O-GlcNAcylation and O-phosphorylation that 
controls enzyme activity, DNA binding, protein–protein interactions, the half-life 
of proteins and their sub-cellular localization. Elucidation of the specific roles of 
O-GlcNAc in transcription, cell signalling, glucose toxicity and insulin resistance 
should lead to new avenues for the diagnosis and treatment of diabetes.69 
A novel mechanism of the antioxidant effect of LA in diabetes progression 
through decreased O-GlcNAcylation of the key proteins that are involved in 
redox signalling pathways was hypothesized.70,71 In these experiments, LA was 
applied at a dose of 10 mg kg–1 i.p., which corresponds to 600 mg LA day–1 in 
humans for 4 weeks, starting from the last day of STZ administration (40 mg kg–1 
i.p. for 5 consecutive days). These studies focused on the antioxidant defence 
system of red blood cells (RBC) and kidneys. RBC are exposed to some of the 
highest levels of oxidative stress in the body because they continuously transport 
oxygen and are the first cellular structures to respond to increased ROS presence. 
RBC damage is a reflection of the general state of oxidative stress in the whole 
organism.72 In the hyperglycaemic environment, RBCs are subjected to compo-
sitional changes and are affected at the functional level.73 In agreement with 
other reports, enzymatic silencing of CuZnSOD and CAT in RBC under diabetic 
conditions were observed,74,75 which was associated with increased levels of O-
GlcNAc-modification of CuZnSOD and CAT, and of the heat shock proteins 
HSP70 and HSP90.70 In vitro studies showed that glycosylation causes a 40 % 
lowering of CuZnSOD activity in RBC.76 It was shown that LA administration to 
diabetic rats preserved the structural and functional integrity of RBC by adjusting 
the redox disturbance and by decreasing the O-GlcNAcylation of SOD and CAT. 
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It was hypothesized that the induction of HSP90 and the lowering of the levels of 
O-GlcNAc-modification of HSP70 and HSP90 as a result of the LA treatment is 
an important defence mechanism in RBC, since HSPs monitor, protect and main-
tain the structure and stability of erythrocyte proteins. These results are valuable 
because functional and healthy RBC could delay or inhibit further diabetic com-
plications, especially neuropathy. 
The renal-protective effect of LA is associated with a reduction of oxidative 
stress.77 Recently performed work revealed that LA administration activates a 
coordinated cytoprotective response against diabetes-induced oxidative injury in 
kidneys through an O-GlcNAc-dependent mechanism, which influences the ex-
pression and activities of CuZnSOD and CAT. The observed upregulation of the 
antioxidant enzyme genes during LA treatment in diabetic kidney was accom-
panied by nuclear translocation of the nuclear factor-erythroid-2-related factor 
(Nrf2), enhanced expression of HSPs and by a reduction of O-GlcNAcylation of 
HSP90 and HSP70, and of the extra-cellular regulated kinase (ERK) and p38. 
Under unstressed conditions, Nrf2 resides in the cytoplasm as an inactive com-
plex bound to a repressor molecule known as Keap1 (Kelch-like ECH-associated 
protein 1) that facilitates its ubiquitination.78 Upon activation, Nrf2 translocates 
to the nucleus where it heterodimerizes with specific cofactors and coordinates 
the upregulation of cytoprotective genes through the initiation of transcription at 
an antioxidant response element (ARE).79 In addition, it was reported that HSP90 
interaction with Keap1 can mediate Nrf2 activation.80 LA can oxidize critical 
thiols on the Keap1 dimer to halt Nrf2 degradation and to prevent Keap1 from 
binding newly synthesized Nrf2. LA also activates the protein kinase signalling 
pathways that lead to the phosphorylation of Ser40 on Nrf2, allowing it to dis-
sociate from Keap1 and to translocate to the nucleus.42 Inhibition of nitrogen-
activated kinases (MAPKs), ERK and p38 prevents the accumulation of Nrf2 in 
the nucleus independently of its phosphorylation.81 It was suggested that MAPK-
mediated phosphorylation of molecular chaperones or some other type of 
accessory protein is required for Nrf2 nuclear translocation.82 Based on our 
obtained results and existing literature data, a model that illustrates the potential 
mechanisms by which LA ameliorates kidney damage in diabetes by inducing 
SOD and CAT expression is presented in Fig. 1. 
6. POSITIVE EFFECTS OF L. deterrimus (Ld) AND C. sativa (Cs) EXTRACTS AND 
THEIR COMBINATION (MIX Ld/Cs) ON β-CELL SURVIVAL 
Examination of compounds and factors that can regulate β-cell survival, 
growth and functioning is of great interest in the context of the prevention of 
diabetes development and its progress. The antioxidant properties and beneficial 
effects of extracts obtained from the edible mushroom Lactarius deterrimus (Ld), 
the sweet chestnut Castanea sativa (Cs) and their combination (MIX Ld/Cs) on 
STZ-induced rat pancreatic β-cell (Rin-5F cells) death have been described.83,84 
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Fig. 1. Potential mechanisms of LA-regulated SOD and CAT gene expression in kidneys of 
diabetic rats. Pathway A illustrates LA-induced protein expression of HSPs and their 
decreased O-GlcNAc modifications that could influence their interaction with Keap1, causing 
a subsequent release of Nrf2 (A1) and/or formation of HSP-Nrf2 heterocomplex that 
translocates to the nucleus and binds ARE (A2), promoting the transcription of genes for 
MnSOD, CuZnSOD and CAT. In a LA-orchestrated O-GlcNAc-dependent mechanism 
(pathway B), reduced O-GlcNAc modification of ERK and p38 could enhance their activity. 
Activated ERK and p38 could phosphorylate a certain Nrf2-binding protein (Nrf2-B.P.) that 
could assist the nuclear translocation of Nrf2 released from Keap1. 
The Cs extract exhibited a remarkably high level of antioxidant activity in vitro, 
while the Ld extract displayed good H2O2 and NO scavenging activities. MIX 
Ld/Cs demonstrated strong antioxidant effects in vitro, and astonishingly, a very 
effective Fe2+ chelating effect, despite the very low individual chelating activities 
of the Ld and Cs extracts. This is in correlation with the concept that no single 
antioxidant can replace the health benefits of a combination of natural phytoche-
micals because of their additive and synergistic effects.51 Each extract and espe-
cially their combination increased Rin-5F cell viability after the STZ treatment as 
a result of a significant reduction in DNA damage and improved redox status. It 
is suggested that different mechanisms underlie the antioxidant effects of Cs, Ld 
and MIX Ld/Cs (Fig. 2). The antioxidant property of the Cs extract probably re-
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lies on its ROS scavenging activity.55,83,85,86 It directly correlates with the ex-
tremely high content of phenolic compounds, especially of hydrolysable tannins 
(ellagic and gallic acids and their derivatives). The beneficial biological effects of 
these compounds in vivo are related to the high free radical-scavenging activity 
they exhibit in vitro.87 The antioxidant properties of the Ld can be explained by a 
strong NO scavenging activity. The low phenolic content of the Ls extract sug-
gests that some other non-phenolic compounds or secondary metabolites88 were 
responsible for its beneficial effect, such as the essential trace elements Se and 
Zn. Se functions as a cofactor of some antioxidant enzymes,89 while Zn protects 
enzyme sulfhydryls from oxidation and reduces the formation of the hydroxyl ra-
dical from H2O2 by competing with redox-active transition metals.90 It is sug-
gested that the MIX Ld/Cs displayed the most beneficial effect on cell survival 
through the additive and synergistic effects of the different antioxidant activities 
contained in Cs and Ld extracts.56 These results provide compelling evidence 
that mixtures of extracts acquire new qualities with respect to the individual ex-
tracts and individual components. This feature explains the improved antioxidant 
and beneficial effects that were exerted on β-cells. 
 
Fig. 2. Potential mechanism of Cs, Ld and MIX Ld/Cs action on the improvement of Rin-5F 
cell redox status and survival. 
The antioxidant properties of the mushroom and chestnut extracts need to be 
confirmed in vivo on a rat model of STZ-induced diabetes (work in progress). 
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Duly aware of the limitations of the in vitro model system, it is proposed that the 
MIX Ld/Cs can reduce oxidative stress in β-cells and that it could thereby 
potentially attenuate the process that underlies the development and progression 
of diabetes. 
7. EFFECTS OF β-GLUCANS ON DIABETES AND THE ASSOCIATED 
COMPLICATIONS 
Natural products containing β-glucans as active components have been pro-
posed to improve general health.91–93 β-Glucans belong to a group of polysac-
charides that are characterized by their location in the cell wall. Some microor-
ganisms, mushrooms and cereals, such as barley and oats, are rich in β-glucans.94 
The macromolecular structure of β-glucans depends on both the source and me-
thod of isolation. The biological activities of β-glucans are determined by their 
primary structure, solubility, degree of branching, molecular weight, the charge 
on their polymers and structure in aqueous media.95 On reviewing the literature, 
it became obvious that the observed effects of β-glucans and glucan-containing 
products are controversial.96 While there are reports that emphasize the immune 
stimulatory97,98 and pro-inflammatory effects of β-glucans,99 as well as in-
creased generation of ROS,100 other studies described their free radical scaveng-
ing activities,101 and anti-inflammatory102 and antioxidative effects.103 Among 
several mechanisms proposed for the protective effects of β-glucan, a major one 
is related to its antioxidant activity.104 
β-Glucans have shown great potential in the treatment of diabetes.92 They 
are effective in lowering blood glucose concentrations and decreasing hyperlipi-
daemia and hypertension. In addition, β-glucans also promote wound healing and 
alleviate ischemic heart injury. Foods containing β-glucans have been used in 
clinical trials in the treatment of diabetes.105,106 Our preliminary results are based 
on observations obtained after treating STZ-induced diabetic rats with a comer-
cially available β-glucan-enriched extract (80 mg kg–1 for four weeks, starting 
from the last day of STZ treatment). Treating diabetic rats with β-glucan pro-
moted a systemic improvement that could be expected to increase the resistance 
of the organism to the onset of diabetic complications. The beneficial effect of 
the β-glucan-enriched extract against diabetes-associated liver and kidney injury 
was mediated through its hyperglycaemia lowering, anti-inflammatory and anti-
oxidant actions. It was speculated that the observed properties of the applied com-
mercial β-glucan-enriched extract could be attributed to the effects of β-glucan 
and other components of the preparation. Mechanisms underlying its effect on 
diabetes and associated complications need to be investigated using pure β-glucan. 
8. CONCLUSIONS 
Despite numerous strategies designed to improve different diabetes-related 
symptoms, the current control of diabetes-associated complications and mortality 
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is not satisfactory. Targeting of oxidative stress in the management of diabetes 
using synthetic antioxidants, such as vitamins A, C and E, yielded limited results 
and the presence of side effects. This has renewed interest in the therapeutic 
potential of bioavailable compounds, extracts and complex mixtures. Due to the 
relatively lower number of side effects and lower cost, naturally derived sub-
stances provide a useful source of potential novel anti-diabetogenic pharmaceu-
tical entities and dietary supplements to existing therapies. Considering that phy-
tochemicals can reduce the major risk factors in diabetes, such as hypergly-
caemia, hyperlipidaemia and oxidative stress, the use of medicinal plants repre-
sents a promising approach for treating diabetes. It is therefore imperative to con-
tinuously identify naturally occurring products with antioxidant activities for use 
in the “causal” therapy of diabetes. 
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Терапија антиоксидансима заузима значајно место у лечењу дијабетеса с обзиром 
да оксидативни стрес у великој мери доприноси нарушавању функције и структуре β-ће-
лија панкреаса као и развоју компликација у дијабетесу. Због ограниченог дејства посто-
јећих антиоксидативних једињења трага се за новим терапијским решењима у третману 
дијабетеса, као што је повећање ендогене антиоксидативне заштите организма путем 
фармаколошке модулације кључних антиоксидативних ензима. Примена биљних екс-
траката у лечењу дијабетеса постаје све популарнија. Многе супстанце које се налазе у 
саставу виших биљака и гљива поседују антиоксидативна својства која могу да заштите 
ткива од штетних утицаја слободних радикала. У овом ревијалном раду описани су екс-
периментални модели дијабетеса као и могући механизми који леже у основи анти-
оксидативног дејства α-липонске киселине (LA), снажног антиоксиданса и једињења које 
стимулише ћелијску апсорпцију глукозе, као и биљних екстраката изолованих из слатког 
кестена (Castanea sativa), јестивих печурака (Lactarius deterrimus) и природних производа 
који садрже β-глукан у лечењу дијабетеса. Описани су њихова улога у спречавању смрти 
β-ћелија панкреаса као и благотворно дејство на компликације у дијабетесу. 
(Примљено 26. октобра, ревидирано 6. децембра 2012) 
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